Working… Menu
Trial record 12 of 25 for:    gestodene

Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03531437
Recruitment Status : Terminated (problem with recruiting participants)
First Posted : May 21, 2018
Last Update Posted : May 21, 2018
Information provided by (Responsible Party):
Nalinee Panichyawat, Mahidol University

Brief Summary:
The purpose of this study is to compare the effects of Zoely® and Minidoz® on hemostatic profiles

Condition or disease Intervention/treatment Phase
Contraception Hypercoagulability Drug: 1.5 mg estradiol and 2.5 mg nomegestrol acetate Drug: 15 µg ethinylestradiol and 60 µg gestodene Phase 4

Detailed Description:
compare the effects of Zoely® and Minidoz® on hemostatic profiles : D-dimer, Antithrombin and fibrinogen

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial
Study Start Date : March 2016
Actual Primary Completion Date : January 2018
Actual Study Completion Date : April 18, 2018

Arm Intervention/treatment
Active Comparator: Zoely
Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
Drug: 1.5 mg estradiol and 2.5 mg nomegestrol acetate
Other Name: Zoely®

Active Comparator: Minidoz
Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
Drug: 15 µg ethinylestradiol and 60 µg gestodene
Other Name: Minidoz®

Primary Outcome Measures :
  1. D-dimer [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. fibrinogen [ Time Frame: 12 weeks ]

  2. antithrombin III [ Time Frame: 12 weeks ]

  3. to access menstrual cycle and bleeding pattern, side effects of Zoely® and Minidoz® [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Woman age 19-40 yr
  • Normal uterus and both adnexae
  • BMI < 28.5 kg/m2
  • Require contraception with COCs

Exclusion Criteria:

  • Pregnancy
  • Postartum period within 6 wk
  • Smoking
  • BP ≥ 140/90 mmHg
  • Contraindication to COCs : VTE, cerebrovascular disease, cardiovascular disease, migraine with aura, hepatitis, undiagnosed abnormal uterine bleeding, CA breast, DM with DN/DR
  • use of liver-enzyme-inducing drugs, drugs affecting the haemostatic system
  • Use contraceptive steroids within 3 months

Layout table for additonal information
Responsible Party: Nalinee Panichyawat, Siriraj hospital, Mahidol University Identifier: NCT03531437     History of Changes
Other Study ID Numbers: 656/2558 (Si726/2015)
First Posted: May 21, 2018    Key Record Dates
Last Update Posted: May 21, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Polyestradiol phosphate
Ethinyl Estradiol
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Antineoplastic Agents, Hormonal
Antineoplastic Agents